An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

University of Santiago de Compostela

Status and phase: Not yet enrolling; Phase 4

Conditions: Bacteremia; Endocarditis

Treatments: Drug: Clindamycin; Drug: Doxycycline

Study type: Interventional

Funder types: Other

Identifiers

NCT06422221

Doxycycline Regimen

Details and patient eligibility

About

Although controversy exists regarding the efficacy of antibiotic prophylaxis for patients at risk of infective endocarditis, expert committees continue to publish recommendations for antibiotic prophylactic regimens. The last American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines include several important changes, highlighting that clindamycin (CLI) is no longer recommended as an alternative to amoxicillin in those allergic to penicillin. This new project aims to evaluate the effectiveness of oral doxycycline in preventing post-dental extraction bloodstream infection.

Full description

PURPOSE: Despite the controversy about the risk of developing bacterial endocarditis of oral origin, numerous Expert Committees in different countries continue to publish prophylactic regimens. To date, the literature is unclear about the role of antimicrobial prophylaxis in the prevention of bacteremia following dental procedures. The aim of this study is to evaluate the efficacy of prophylactic dosage with oral doxycycline (DXC) in the prevention of bacteremia following dental extractions.

SELECTION OF THE STUDY GROUP AND STUDY DESIGN: The study group will comprise patients who, for behavioral reasons (autism, learning disabilities, phobias, etc.), will undergo dental extractions under general anesthesia in the Santiago de Compostela University Hospital (Santiago de Compostela, Spain). 150 patients will be selected and will be randomly distributed into 3 study groups: control group (receiving no prophylaxis), CLI group (receiving 600 mg oral CLI) and DXC group (receiving 100 mg oral DXC).

COLLECTION OF SAMPLES FOR BLOOD CULTURE: To determine the prevalence of bacteremia, a peripheral venous blood sample (10 ml) will be drawn from each patient. Samples will be inoculated in BACTEC plus (Becton Dickinson and Company, Sparks, MD) aerobic and anaerobic blood culture bottles, and will be processed in the Bactec 9240 (Becton Dickinson).

MICROBIOLOGICAL ANALYSIS OF BLOOD CULTURES: A Gram stain will be performed on each positive blood culture. The positive blood cultures in the aerobic media will be subcultured on blood agar and chocolate agar in an atmosphere of 5 to 10% carbon monoxide and on MacConkey agar under aerobic conditions. The same protocol will be used for the positive blood cultures in the anaerobic media, with subculture on Schaedler agar and incubation in an anaerobic atmosphere. The bacteria isolated will be identified by using the battery of biochemical tests provided with the Vitek system for Gram-positive bacteria, Neisseria spp., Haemophilus spp., and obligate anaerobic bacteria. The viridans group streptococci will be classified into five groups, the Streptococcus mitis, S. anginosus, S. salivarius, S. mutans, and S. bovis groups, by applying the Ruoff criteria. Facklam's criteria will be used to identify unusual Streptococcus spp. and other Gram-positive cocci in chains.

The subculture and further identification of the isolated bacteria will be performed by conventional microbiological techniques. The collection, handling, and transport of the blood samples for blood culture will be performed according to the recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must have at least 10 teeth.
• Subjects must have the need for a dental extraction under general anesthesia (for behavioral reasons).
• Subjects will be recruited regardless of the extent and severity of their dental and/or periodontal disease.

Exclusion criteria

• Age under 18 years
• Body weight under 40 kg
• Receipt of antibiotics in the previous 3 months
• Routine use of oral antiseptics
• A history of allergy or intolerance to doxycycline
• A history of allergy or intolerance to cindamycin
• Any type of congenital or acquired immunodeficiency
• Any known risk factor for bacterial endocarditis
• Any known risk factor for prolonged bleeding

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

150 participants in 3 patient groups

No Intervention

No Intervention group

Description:

Receiving no prophylaxis

Clindamycin

Active Comparator group

Description:

Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation

Treatment:

Drug: Clindamycin

Doxycycline

Active Comparator group

Description:

Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation

Treatment:

Drug: Doxycycline